Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Corporate Authors:
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Background: The hyperglycemic clamp test, the gold standard of beta cell function, predicts impending type 1 diabetes in islet autoantibody-positive individuals, but the latter may benefit from less invasive function tests such as the proinsulin:C-peptide ratio (PI:C). The present study aims to optimize precision of PI:C measurements by automating a dual-label trefoil-type time-resolved fluorescence immunoassay (TT-TRFIA), and to compare its diagnostic performance for predicting type 1 diabetes with that of clamp-derived C-peptide release.
Methods: Between-day imprecision (n = 20) and split-sample analysis (n = 95) were used to compare TT-TRFIA (AutoDelfia, Perkin-Elmer) with separate methods for proinsulin (in-house TRFIA) and C-peptide (Elecsys, Roche). High-risk multiple autoantibody-positive first-degree relatives (n = 49; age 5-39) were tested for fasting PI:C, HOMA2-IR and hyperglycemic clamp and followed for 20-57 months (interquartile range).
Results: TT-TRFIA values for proinsulin, C-peptide and PI:C correlated significantly (r2 = 0.96-0.99; P<0.001) with results obtained with separate methods. TT-TRFIA achieved better between-day %CV for PI:C at three different levels (4.5-7.1 vs 6.7-9.5 for separate methods). In high-risk relatives fasting PI:C was significantly and inversely correlated (rs = -0.596; P<0.001) with first-phase C-peptide release during clamp (also with second phase release, only available for age 12-39 years; n = 31), but only after normalization for HOMA2-IR. In ROC- and Cox regression analysis, HOMA2-IR-corrected PI:C predicted 2-year progression to diabetes equally well as clamp-derived C-peptide release.
Conclusions: The reproducibility of PI:C benefits from the automated simultaneous determination of both hormones. HOMA2-IR-corrected PI:C may serve as a minimally invasive alternative to the more tedious hyperglycemic clamp test.
Competing Interests: The authors have declared that no competing interests exist.
- Comments:
Erratum in: PLoS One. 2017 Jun 1;12 (6):e0179108. (PMID: 28570714)
- References:
Int J Mol Sci. 2016 May 17;17(5):. (PMID: 27196896)
Am J Epidemiol. 2007 Mar 15;165(6):710-8. (PMID: 17182981)
Eur J Endocrinol. 2013 Sep 14;169(4):479-85. (PMID: 23904276)
Diabetes Care. 2004 Jun;27(6):1433-8. (PMID: 15161800)
Clin Chem. 2008 Dec;54(12):1990-8. (PMID: 18845769)
Diabetologia. 2016 Jun;59(6):1186-95. (PMID: 26995649)
Expert Rev Clin Immunol. 2013 Dec;9(12):1173-83. (PMID: 24215407)
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 1;877(23):2403-6. (PMID: 19041285)
Diabetes Care. 1997 Jun;20(6):1027-33. (PMID: 9167119)
Semin Immunol. 2011 Jun;23(3):174-81. (PMID: 21846589)
Diabetologia. 2010 Jan;53(1):36-44. (PMID: 19898832)
Diabetes Care. 2016 Sep;39(9):1519-26. (PMID: 27385327)
Transl Res. 2016 Feb;168:96-106.e1. (PMID: 26397425)
JAMA. 2013 Jun 19;309(23):2473-9. (PMID: 23780460)
Diabetologia. 2005 Nov;48(11):2322-9. (PMID: 16211374)
Diabetes Care. 2015 May;38(5):808-13. (PMID: 25665818)
Diabet Med. 2013 Feb;30(2):161-9. (PMID: 23231526)
Diabetologia. 1999 Sep;42(9):1060-6. (PMID: 10447516)
Diabetes Care. 2008 Jan;31(1):146-50. (PMID: 17959864)
J Clin Endocrinol Metab. 1998 Feb;83(2):604-8. (PMID: 9467581)
Clin Chem. 2006 Jun;52(6):1193-6. (PMID: 16613996)
Diabetes. 2015 May;64(5):1719-27. (PMID: 25524912)
Diabetologia. 2015 Dec;58(12):2753-64. (PMID: 26409458)
Diabetologia. 2010 Mar;53(3):517-24. (PMID: 20091020)
J Clin Endocrinol Metab. 1994 Dec;79(6):1570-5. (PMID: 7989457)
Clin Chem. 1993 Oct;39(10):2146-50. (PMID: 8403400)
Am J Physiol. 1979 Sep;237(3):E214-23. (PMID: 382871)
Clin Chim Acta. 1983 Mar 28;129(1):103-6. (PMID: 6851148)
Diabetes. 1993 Feb;42(2):213-20. (PMID: 8425658)
Clin Exp Immunol. 2013 Jan;171(1):82-90. (PMID: 23199327)
Endocrinology. 2010 Oct;151(10):5048-52. (PMID: 20702574)
Diabetes Care. 1996 Mar;19(3):278-86. (PMID: 8742583)
J Immunol Methods. 1996 Dec 15;199(2):127-38. (PMID: 8982354)
Diabetes Care. 2011 Jun;34(6):1397-9. (PMID: 21562325)
Diabetes. 1997 Dec;46(12):1990-5. (PMID: 9392485)
Diabetes Care. 2016 Sep;39(9):1653. (PMID: 27555625)
J Clin Endocrinol Metab. 2015 Feb;100(2):551-60. (PMID: 25405499)
Clin Sci (Lond). 1996 Jul;91(1):65-71. (PMID: 8774262)
Biometrics. 1988 Sep;44(3):837-45. (PMID: 3203132)
Diabetes Care. 1999 Feb;22(2):262-70. (PMID: 10333943)
Diabetes Care. 2015 Oct;38(10):1964-74. (PMID: 26404926)
- Accession Number:
0 (Autoantibodies)
0 (C-Peptide)
0 (Glycated Hemoglobin A)
0 (Insulin)
0 (hemoglobin A1c protein, human)
9035-68-1 (Proinsulin)
- Publication Date:
Date Created: 20161202 Date Completed: 20170630 Latest Revision: 20231111
- Publication Date:
20240829
- Accession Number:
PMC5131964
- Accession Number:
10.1371/journal.pone.0166702
- Accession Number:
27907006
No Comments.